Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Participant has operable stage I-IIIa breast cancer of the following subtypes: (1) estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; (2) ER-positive tumor meeting one of the following criteria: histologic grade 3; histologic grade 2 and PR-negative; histologic grade 2 and Ki67 antigen ≥10%. Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam
Participant is female and ≥18 years of age
You may not be if
Participant is pregnant, breastfeeding or planning to become pregnant while in the study
Participant has received prior chemotherapy, biological therapy or radiation
Participant has participated in a clinical trial in the last 30 days
Participant has a history of drug or alcohol abuse in the last year
Participant is human immunodeficiency virus (HIV) positive. Patient has a history of Hepatitis B or C
Participant has poorly controlled diabetes mellitus
Clareo Health | A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013)
